<DOC>
	<DOC>NCT02834780</DOC>
	<brief_summary>The primary purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527 (Part 1), and to assess the safety and tolerability of H3B-6527 as a single agent administered orally (Part 2) in participants with advanced hepatocellular carcinoma (HCC).</brief_summary>
	<brief_title>Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Inclusion criteria: 1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 2. Presence of at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) 3. Participants with hepatocellular carcinoma who have progressed despite standard therapy or are intolerant of standard therapy Exclusion criteria: 1. Participants with brain or subdural metastases, unless previously treated and stable 2. Known human immunodeficiency virus (HIV) infection 3. Previous treatment with Fibroblast growth factor receptor 4 (FGFR4) targeted therapy 4. Presence of gastric or esophageal varices requiring active treatment 5. Significant cardiovascular impairment or any other major illness 6. Females who are pregnant or breastfeeding Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Hepatocellular Carcinoma</keyword>
	<keyword>H3B-6527</keyword>
</DOC>